Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Post by MrMugsyon Mar 31, 2021 9:01am
275 Views
Post# 32912707

Annual Report is now available ...

Annual Report is now available ...Rest of world strategy Knight has successfully completed the acquisition of 99.9% of Grupo Biotoscana and made significant headway in the integration of ten countries in Latin America and 700 employees. With this acquisition, Knight has established a strong panAmerican (ex-US) infrastructure which enables Knight to become a one stop shop and a partner of choice for pharmaceutical companies looking to commercialize their innovative products.


Financial Results • Revenues were $199,519, an increase of $152,058 or 320% over prior year. • Gross margin generated of $81,690 or 41% compared to $26,918 or 57% in prior year. • Adjusted EBITDA1 was $16,837 compared to $2,827 in prior year. • Interest income generated of $14,322 a decrease of $9,220 or 39% over prior year. • Gain from strategic fund investments of $46,733, of which $16,644 was realized. • Adjusted earnings1 of $28,713, an increase of $2,714 or 10% over prior year. • Net income was $31,760 compared to net income of $18,033 in prior year.

Corporate Development • Promoted Arvind Utchanah from VP Finance to CFO. • Accepted the resignation of Nancy Harrison, Sylvie Tendler and Kevin Cameron and appointed Janice Murray and Nicols Sujoy on the Board of Directors. • Disposed the shares of Medison for a cash consideration of $77,000 and recorded a gain of $2,948. • Purchased 5,748,716 common shares and at an average price of $6.40 per share through a NCIB. • Completed the tender offer process for an aggregate purchase price of $170,855 and achieved 99.9% ownership of GBT. • Filed a short form base shelf prospectus in December 2020 which enables Knight to offer for sale and issue up to $360,000 in common shares, subscription receipts and debt securities from time to time during the 25-month period during which the shelf prospectus remains valid.

-------------------

Foundation in place.
Profitable.
Washed their hands of Meir/Cameron (and that soap opera)
Now they need to improve the efficiencies of GBT and the business as a whole - lots of low hanging fruit (if you will).
<< Previous
Bullboard Posts
Next >>